½ÃÀ庸°í¼­
»óǰÄÚµå
1789532

¸¶¿îÀÚ·Î(Mounjaro) ½ÃÀå : °­µµº°, Á¦Çüº°, À¯Åë ä³Îº°, Áö¿ªº°

Mounjaro Market, By Strength, By Dosage Form, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¸¶¿îÀÚ·Î ½ÃÀåÀº 2025³â¿¡ 167¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 554¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGRÀº 18.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 167¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 18.60% 2032³â °¡Ä¡ ¿¹Ãø 554¾ï 8,000¸¸ ´Þ·¯

¼¼°è ¸¶¿îÀÚ·Î ½ÃÀåÀº Eli Lilly and Company°¡ °³¹ßÇÑ È¹±âÀûÀÎ Æ÷µµ´ç ÀÇÁ¸¼º Àν¶¸° ºÐºñ ÃËÁø Æú¸®ÆéŸÀ̵å(GIP)¿Í ±Û·çÄ«°ï À¯»ç ÆéŸÀ̵å-1(GLP-1) ¼ö¿ëü ÀÌÁß ÀÛ¿ëÁ¦ÀÎ Æ¿Á¦ÆÄŸÀ̵å(Tilzepatide)¸¦ Áß½ÉÀ¸·Î ÇÑ Á¦¾à ¾÷°èÀÇ Çõ¸íÀûÀÎ ºÎ¹®ÀÔ´Ï´Ù. ¸¶¿îÀڷδ ÁÖ·Î 2Çü ´ç´¢º´ Ä¡·á¸¦ ÀûÀÀÁõÀ¸·Î Çϴ ȹ±âÀûÀÎ Ä¡·áÁ¦·Î µîÀåÇÏ¿© Ç÷´ç Á¶Àý¿¡ Ź¿ùÇÑ È¿°ú¿Í »ó´çÇÑ Ã¼Áß °¨¼Ò È¿°ú¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÀÌ Çõ½ÅÀûÀÎ ¾à¹°Àº µ¶Æ¯ÇÑ ÀÌÁß È£¸£¸ó Á¢±Ù¹ýÀ» ÅëÇØ GIP¿Í GLP-1 ¼ö¿ëü¸¦ µ¿½Ã¿¡ Ç¥ÀûÀ¸·Î »ï¾Æ Àν¶¸° ºÐºñ¸¦ ÃËÁøÇÏ°í ±Û·çÄ«°ï ºÐºñ¸¦ ¾ïÁ¦Çϸç À§ ¹èÃâÀ» ¿ÏÈ­ÇÔÀ¸·Î½á ±âÁ¸ ´ÜÀÏ ¿ä¹ý ´ëºñ ¿ì¼öÇÑ Ç÷´ç Á¶Àý È¿°ú¸¦ ³ªÅ¸³À´Ï´Ù. ÇöÀç ÁøÇà ÁßÀÎ ÀÓ»ó½ÃÇè¿¡¼­´Â ºñ¸¸ Ä¡·á ¹× ½ÉÇ÷°ü À§Çè °¨¼Ò¿¡ ´ëÇÑ Àû¿ë °¡´É¼ºÀ» °ËÅäÇϰí ÀÖ¾î, ¸ð¿õ°¡·Î°¡ ´ÙÀç´Ù´ÉÇÑ Ä¡·áÁ¦·Î ÀÚ¸®¸Å±èÇÒ ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëÇϰí ÀÖ½À´Ï´Ù. Á¦¾à ¾÷°è¿¡¼­´Â º´¿ë¿ä¹ý ¹× ¸ÂÃãÀÇ·á¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁö¸é¼­ ¸¶¿îÀÚ·ÎÀÇ ÀÌÁß ÀÛ¿ë±âÀü¿¡ ´ëÇÑ °ü½ÉÀÌ ´õ¿í ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ¸¶¿îÀڷδ ÁøÈ­ÇÏ´Â ´ç´¢º´ Ä¡·á »ýŰ迡¼­ ÇÙ½É Á¦Ç°ÀÌÀÚ, Å« ¼ºÀå ÀáÀç·ÂÀ» °¡Áø ÇÁ¸®¹Ì¾ö Ä¡·á ¿É¼ÇÀ¸·Î ½ÃÀå¿¡¼­ ÀÔÁö¸¦ ´ÙÁö°í ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

¸¶¿îÀÚ·Î ¼¼°è ½ÃÀåÀº °­·ÂÇÑ ¼ºÀå ±Ëµµ¿Í ½ÃÀå ħÅõ °¡´É¼ºÀ» °­Á¶ÇÏ´Â ¸î °¡Áö °­·ÂÇÑ ÃËÁø¿äÀο¡ ÀÇÇØ µÞ¹ÞħµÇ°í ÀÖ½À´Ï´Ù. ±¹Á¦´ç´¢º´¿¬¸ÍÀº 2045³â±îÁö Àü ¼¼°èÀûÀ¸·Î 7¾ï ¸í ÀÌ»óÀÇ ´ç´¢º´ ȯÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¸¶¿îÀÚ·Î¿Í °°Àº Çõ½ÅÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Àü·Ê ¾ø´Â ¼ö¿ä¸¦ ºÒ·¯ÀÏÀ¸Å°°í ÀÖ½À´Ï´Ù. ÀÓ»ó 3»ó ½ÃÇè¿¡¼­ ÃÖ´ë 15%ÀÇ Ã¼Áß °¨¼Ò¿Í HbA1c¸¦ À¯ÀǹÌÇÏ°Ô °³¼±ÇÏ´Â µî ¿ì¼öÇÑ ÀÓ»óÀû È¿°ú°¡ ÀÔÁõµÇ¾î Á¾ÇÕÀûÀÎ ´ç´¢º´ °ü¸®¸¦ ¿øÇÏ´Â ÀÇ·áÁø°ú ȯÀڵ鿡°Ô ¼±È£µÇ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´ °ü·Ã ÇÕº´Áõ¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¿Í ¿¹¹æÀû °Ç°­°ü¸®·ÎÀÇ ÀüȯÀÌ ½ÃÀå µµÀÔÀÇ ¿øµ¿·ÂÀÌ µÇ°í ÀÖÀ¸¸ç, ½ÅÈï±¹ ½ÃÀåÀÇ À¯¸®ÇÑ »óȯ Á¤Ã¥ ¹× º¸Çè Àû¿ë ¹üÀ§ È®´ë°¡ ½ÃÀå µµÀÔÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ½ÃÀåÀº ¶Ñ·ÇÇÑ ¾ïÁ¦¿äÀο¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¸¶¿îÀڷδ °í°¡À̱⠶§¹®¿¡ °¡°Ý¿¡ ¹Î°¨ÇÑ ½ÃÀåÀ̳ª ½ÅÈï °æÁ¦±¹¿¡¼­ÀÇ ÀÌ¿ëÀÌ Á¦ÇѵǾî Àü ¼¼°è º¸±ÞÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù. ƯÈ÷ ¼ö¿ä°¡ ±ÞÁõÇÏ´Â ½Ã±â¿¡´Â °ø±Þ¸Á ¹®Á¦¿Í Á¦Á¶ È®À强¿¡ ´ëÇÑ ¿ì·Á°¡ ½ÃÀå ¼ºÀå¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¿î¿µ»óÀÇ Á¦¾àÀ¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Áö¸®ÀûÀ¸·Î ¼­·Î ´Ù¸¥ Áö¿ª¿¡ °ÉÄ£ º¹ÀâÇÑ ±ÔÁ¦¿Í »õ·Î¿î ÀûÀÀÁõ¿¡ ´ëÇÑ ½ÂÀÎ ÀýÂ÷ÀÇ Àå±âÈ­´Â ½ÃÀåÀÇ ºü¸¥ ¼ºÀå¿¡ ¶Ç ´Ù¸¥ À庮À¸·Î ÀÛ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¾î·Á¿ò¿¡µµ ºÒ±¸Çϰí, ¸¶¿îÀÚ·ÎÀÇ Ä¡·á ¿ëµµ È®´ë, ƯÈ÷ ÀÓ»ó½ÃÇè¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ º¸ÀÎ ºñ¸¸ °ü¸®¿¡¼­ Å« ºñÁî´Ï½º ±âȸ°¡ âÃâµÇ¾î »õ·Î¿î ¼öÀÍ¿ø°ú ½ÃÀå ºÎ¹®À» °³Ã´ÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù. ¿ø°ÝÀÇ·á ¹× µðÁöÅÐ Çコ Ç÷§ÆûÀÇ µµÀÔÀº ȯÀÚ ¸ð´ÏÅ͸µ ¹× ¼øÀÀµµ ÇÁ·Î±×·¥À» °­È­ÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇϰí, ÇコÄÉ¾î ½Ã½ºÅÛ ¹× ¾à±¹ üÀΰúÀÇ Àü·«Àû Á¦ÈÞ¸¦ ÅëÇØ ½ÃÀå Á¢±Ù¼º ¹× À¯Åë È¿À²À» Çâ»ó½ÃÄÑ ±Ã±ØÀûÀ¸·Î ¼¼°è ´ç´¢º´ Ä¡·áÁ¦ ½ÃÀåÀÇ Àå±âÀûÀÎ Áö¼Ó ¼ºÀåÀ» °¡¼ÓÇÒ ¼ö ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ¸¶¿îÀÚ·Î ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯)¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¼öÀÍ Ã¢Ãâ ±âȸ¸¦ ÆÄ¾ÇÇϰí, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ ÁÖ¿ä ÀλçÀÌÆ®À» Á¦°øÇÕ´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, ¼º°ú, Àü·« µîÀÇ ¸Å°³ º¯¼ö¸¦ ±â¹ÝÀ¸·Î ¼¼°è ¸¶¿îÀÚ·Î ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇÕ´Ï´Ù.
  • À̹ø Á¶»ç ´ë»ó ÁÖ¿ä ±â¾÷À¸·Î´Â Eli Lilly and Company µîÀÌ ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
  • ÀÌ º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ½ÃÀå ÁøÃâ±â¾÷, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
  • ¼¼°è ¸¶¿îÀÚ·Î ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚµéÀÌ ½±°Ô ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

  • Á¶»ç ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • º¸°í¼­ ¼³¸í
    • ½ÃÀå Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • ¿µÇ⠺м®
  • ÁÖ¿ä ¹ßÀü
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • Á¦Ç° ¹ß¸Å/½ÂÀÎ
  • PEST ºÐ¼®
  • PORTERÀÇ ºÐ¼®
  • ÀμöÇÕº´ ½Ã³ª¸®¿À
  • ¾÷°è µ¿Çâ
  • ƯÇã »óȲ
  • ±¹°¡º° ½ÂÀÎ ¸ÅÆ®¸¯½º

Á¦4Àå ¼¼°èÀÇ ¸¶¿îÀÚ·Î ½ÃÀå, °­µµº°, 2022-2032³â

  • 15mg
  • 10mg
  • 12.5mg
  • 7.5mg
  • 5mg
  • 2.5mg

Á¦5Àå ¼¼°èÀÇ ¸¶¿îÀÚ·Î ½ÃÀå, Á¦Çüº°, 2022-2032³â

  • ÀÏȸ Åõ¿© Ææ
  • ÀÏȸ Åõ¿© ¹ÙÀ̾Ë

Á¦6Àå ¼¼°èÀÇ ¸¶¿îÀÚ·Î ½ÃÀå, À¯Åë ä³Îº°, 2022-2032³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦7Àå ¼¼°èÀÇ ¸¶¿îÀÚ·Î ½ÃÀå, Áö¿ªº°, 2023-2032³â

  • ºÏ¹Ì
      • ¹Ì±¹
      • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ¸ß½ÃÄÚ
      • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
      • µ¶ÀÏ
      • ¿µ±¹
      • ½ºÆäÀÎ
      • ÇÁ¶û½º
      • ÀÌÅ»¸®¾Æ
      • ·¯½Ã¾Æ
      • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
      • Áß±¹
      • Àεµ
      • ÀϺ»
      • È£ÁÖ
      • Çѱ¹
      • ASEAN
      • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
      • GCC ±¹°¡
      • À̽º¶ó¿¤
      • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
      • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
      • ºÏ¾ÆÇÁ¸®Ä«
      • Áß¾Ó¾ÆÇÁ¸®Ä«

Á¦8Àå °æÀï ±¸µµ

  • Eli Lilly and Company

Á¦9Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

  • ±âȸ
  • ¾Ö³Î¸®½ºÆ®ÀÇ °ßÇØ
  • Coherent Opportunity Map

Á¦10Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

  • Âü°í¹®Çå
  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSM

Mounjaro Market is estimated to be valued at USD 16.78 Bn in 2025 and is expected to reach USD 55.48 Bn by 2032, growing at a compound annual growth rate (CAGR) of 18.6% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: USD 16.78 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 18.60% 2032 Value Projection: USD 55.48 Bn

The global Mounjaro market represents a revolutionary segment within the pharmaceutical landscape, centered around tirzepatide, a groundbreaking dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly and Company. Mounjaro has emerged as a transformative therapeutic solution primarily indicated for the treatment of type 2 diabetes mellitus, demonstrating exceptional efficacy in glycemic control and significant weight reduction benefits. This innovative medication operates through a unique dual-hormone approach, simultaneously targeting both GIP and GLP-1 receptors to enhance insulin secretion, suppress glucagon release, and slow gastric emptying, thereby providing superior glucose management compared to traditional monotherapy approaches. The market's significance extends beyond diabetes management, as ongoing clinical trials explore Mounjaro's potential applications in obesity treatment and cardiovascular risk reduction, positioning it as a versatile therapeutic asset. The pharmaceutical industry's increasing focus on combination therapies and personalized medicine has further amplified interest in Mounjaro's dual-action mechanism, making it a cornerstone product in the evolving diabetes care ecosystem and establishing its market presence as a premium therapeutic option with substantial growth potential.

Market Dynamics

The global Mounjaro market is propelled by several compelling drivers that underscore its robust growth trajectory and market penetration potential. The primary driver stems from the escalating global prevalence of type 2 diabetes, with the International Diabetes Federation projecting over 700 million diabetes cases worldwide by 2045, creating an unprecedented demand for innovative therapeutic solutions like Mounjaro. The drug's superior clinical efficacy, demonstrated through Phase III trials showing up to 15% weight reduction and significant HbA1c improvements, positions it as a preferred choice among healthcare providers and patients seeking comprehensive diabetes management. Additionally, the growing awareness about diabetes-related complications and the shift toward preventive healthcare approaches drive market adoption, while favorable reimbursement policies and insurance coverage expansions in developed markets further accelerate uptake. However, the market faces notable restraints, including Mounjaro's premium pricing structure that limits accessibility in price-sensitive markets and developing economies, potentially restricting its global penetration. Supply chain challenges and manufacturing scalability concerns, particularly during peak demand periods, pose operational constraints that could impact market growth. Regulatory complexities across different geographical regions and the lengthy approval processes for new indications create additional barriers to rapid market expansion. Despite these challenges, significant opportunities emerge from Mounjaro's expanding therapeutic applications, particularly in obesity management where clinical trials demonstrate promising results, potentially opening new revenue streams and market segments. The increasing adoption of telemedicine and digital health platforms presents opportunities for enhanced patient monitoring and adherence programs, while strategic partnerships with healthcare systems and pharmacy chains could improve market access and distribution efficiency, ultimately driving sustainable long-term growth in the global diabetes therapeutics landscape.

Key Features of the Study

  • This report provides in-depth analysis of the global Mounjaro market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
  • It profiles key players in the global Mounjaro market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
  • Key company covered as a part of this study includes Eli Lilly and Company.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
  • The global Mounjaro market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global Mounjaro market.

Market Segmentation

  • Strength Insights (Revenue, USD Bn, 2022 - 2032)
    • 15 mg
    • 10 mg
    • 5 mg
    • 5 mg
    • 5 mg
    • 5 mg
  • Dosage Form Insights (Revenue, USD Bn, 2022 - 2032)
    • Single-dose Pen
    • Single-dose Vial
  • Distribution Channel Insights (Revenue, USD Bn, 2022 - 2032)
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Regional Insights (Revenue, USD Bn, 2022 - 2032)
    • North America
    • U.S.
    • Canada
    • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
    • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
    • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
    • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
  • Key Players Insights
    • Eli Lilly and Company

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Global Mounjaro Market, By Strength
    • Global Mounjaro Market, By Dosage Form
    • Global Mounjaro Market, By Distribution Channel
    • Global Mounjaro Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
  • Driver
  • Restraint
  • Opportunity
  • Impact Analysis
  • Key Developments
  • Regulatory Scenario
  • Product Launches/Approvals
  • PEST Analysis
  • PORTER's Analysis
  • Merger and Acquisition Scenario
  • Industry Trends
  • Patent Landscape
  • Country Approval Matrix

4. Global Mounjaro Market, By Strength, 2022-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2023 - 2032
    • Segment Trends
  • 15 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • 10 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • 12.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • 7.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • 5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • 2.5 mg
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)

5. Global Mounjaro Market, By Dosage Form, 2022-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2023 - 2032
    • Segment Trends
  • Single-dose Pen
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • Single-dose Vial
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)

6. Global Mounjaro Market, By Distribution Channel, 2022-2032, (USD Bn)

  • Introduction
    • Market Share Analysis, 2025 and 2032 (%)
    • Y-o-Y Growth Analysis, 2023 - 2032
    • Segment Trends
  • Hospital Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2022 - 2032, (USD Bn)

7. Global Mounjaro Market, By Region, 2023 - 2032, Value (USD Bn)

  • Introduction
    • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
    • Market Y-o-Y Growth Analysis (%), 2023 - 2032, Value (USD Bn)
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2022 - 2032, Value (USD Bn)
      • U.S.
      • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2022 - 2032, Value (USD Bn)
      • Brazil
      • Argentina
      • Mexico
      • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2022 - 2032, Value (USD Bn)
      • Germany
      • U.K.
      • Spain
      • France
      • Italy
      • Russia
      • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2022 - 2032, Value (USD Bn)
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country, 2022 - 2032, Value (USD Bn)
      • GCC Countries
      • Israel
      • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, By Strength, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Age Group, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Dosage Form, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Distribution Channel, 2022 - 2032, Value (USD Bn)
    • Market Size and Forecast, By Country/Region, 2022 - 2032, Value (USD Bn)
      • South Africa
      • North Africa
      • Central Africa

8. Competitive Landscape

  • Eli Lilly and Company
    • Company Highlights
    • Product Portfolio
    • Key Developments
    • Financial Performance
    • Strategies

9. Analyst Recommendations

  • Wheel of Fortune
  • Analyst View
  • Coherent Opportunity Map

10. References and Research Methodology

  • References
  • Research Methodology
  • About us
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦